Zydus Lifesciences Ltd. NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

987.90 -6.75 (-0.68%)

950.5K

NSE+BSE Volume

NSE 07 Oct, 2025 3:31 PM (IST)

Regulatory Approval

Zyuds Life gets Health Canada approval for Liothyronine tablets with a market size of CAD 10.9 mn See details

Zydus Lifesciences Ltd. share price target

Name: Latest research reports of Zydus Lifesciences Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 3
Author: Karvy

Zydus Lifesciences Ltd. has an average share price target of 1045.33. The consensus estimate represents an upside of 5.81% from the last price of 987.90. View 12 reports from 6 analysts offering long-term price targets for Zydus Lifesciences Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
07 Oct 2025	Zydus Lifesciences	Consensus Share Price Target	987.90	1017.50	-	3.00	hold	pdf Detailed Estimates
11 Feb 2015	Zydus Lifesciences	Karvy	987.90		300.81 (228.41%)	Pre-Bonus/ Split	Hold	pdf post cache	Broker Report Cadila Healthcare Ltd:Result Review (Feb 11, 2015) Karvy Cadila's revenues grew by 17% YoY to Rs21.6 bn during the quarter on the back of strong performance in US region. Operating margins improved to 20.4% compared to 15.8% in Q3FY14, higher than our estimates of 19.6%. Net Profit at Rs 2,819 mn grew by 51.7% YoY in Q3FY15 due to better gross margins and lower overheads. pdf Copy Link Share on Share on Share on Share on Alert
31 Oct 2014	Zydus Lifesciences	Ashika Research	987.90		282.00 (250.32%)	Pre-Bonus/ Split	Buy	pdf post cache	Broker Report Cadila Healthcare Ltd. Ashika Research Cadila healthcare (CDH) is a leading Indian pharmaceutical company with strong presence in US generic drug market. The company's key operating segments include US generic, Domestic... pdf Copy Link Share on Share on Share on Share on Alert

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Zydus Lifesciences Ltd. share price target

Zydus Lifesciences Ltd. has an average share price target of 1045.33. The consensus estimate represents an upside of 5.81% from the last price of 987.90. View 12 reports from 6 analysts offering long-term price targets for Zydus Lifesciences Ltd..

Cadila Healthcare Ltd:Result Review (Feb 11, 2015)

Cadila Healthcare Ltd.

Advisor Screeners